Search research articles
Contact Us
Filters
Showing results (871-880 of 1,011) with videos related to
Page
of 102
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
November 5, 2013
Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study
Dana C Miskulin, Kaleab Z Abebe, Arlene B Chapman, et al.
JCO Precision Oncology
|
September 11, 2020
<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma
Federica Catalanotti, Donavan T Cheng, Alexander N Shoushtari, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences
|
November 12, 2021
Novel Oppositional Defiant Disorder 6 Months After Traumatic Brain Injury in Children and Adolescents
Daniel S Lowet, Anish Kolan, Florin Vaida, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
P B Chapman, C Robert, J Larkin, et al.
Journal of Translational Medicine
|
March 24, 2012
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide
Julio D Duarte, Issam Zineh, Ben Burkley, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
Axel Hauschild, Paolo A Ascierto, Dirk Schadendorf, et al.
American Journal of Clinical Oncology
|
October 14, 2009
Radiotherapy after surgical resection for head and neck mucosal melanoma
Abraham J Wu, Jennifer Gomez, Joanne E Zhung, et al.
The Oncologist
|
May 10, 2015
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases
James J Harding, Federica Catalanotti, Rodrigo R Munhoz, et al.
Journal of the American Society of Nephrology : JASN
|
June 4, 2020
Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease
Kyongtae T Bae, Tiange Shi, Cheng Tao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic Melanoma
Yibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
Page
of 102
Search research articles
Search
Showing results (871-880 of 1,011) with videos related to
Sort By:
Page
of 102
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
November 5, 2013
Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study
Dana C Miskulin, Kaleab Z Abebe, Arlene B Chapman, et al.
JCO Precision Oncology
|
September 11, 2020
<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma
Federica Catalanotti, Donavan T Cheng, Alexander N Shoushtari, et al.
The Journal of Neuropsychiatry and Clinical Neurosciences
|
November 12, 2021
Novel Oppositional Defiant Disorder 6 Months After Traumatic Brain Injury in Children and Adolescents
Daniel S Lowet, Anish Kolan, Florin Vaida, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
P B Chapman, C Robert, J Larkin, et al.
Journal of Translational Medicine
|
March 24, 2012
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide
Julio D Duarte, Issam Zineh, Ben Burkley, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2019
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
Axel Hauschild, Paolo A Ascierto, Dirk Schadendorf, et al.
American Journal of Clinical Oncology
|
October 14, 2009
Radiotherapy after surgical resection for head and neck mucosal melanoma
Abraham J Wu, Jennifer Gomez, Joanne E Zhung, et al.
The Oncologist
|
May 10, 2015
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases
James J Harding, Federica Catalanotti, Rodrigo R Munhoz, et al.
Journal of the American Society of Nephrology : JASN
|
June 4, 2020
Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease
Kyongtae T Bae, Tiange Shi, Cheng Tao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic Melanoma
Yibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
Page
of 102